IP Library Granted Patent US 10,293,023
Granted Patent B2
US 10,293,023 · App. 14/771,359 · Granted May 21, 2019

Method of altering vascular permeability and uses thereof

Inventors: Donald E. Ingber (Boston, MA); Akiko Mammoto (Brookline, MA)
Assignee: CHILDREN'S MEDICAL CENTER CORPORATION
A61K38/10A61K31/275A61K31/519A61K31/713A61K38/1841A61K38/39A61K38/44A61N5/062C07K16/28C07K16/40C12N15/1137A61K48/005A61K2039/505A61N2005/0661C07K2317/33C07K2317/34C07K2317/76C12N2310/14C12Y104/03013
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,293,023
App. No.
14/771,359
Granted
May 21, 2019
Kind
B2
Abstract

Provided here are methods of modulating vascular permeability by changing the mechanical properties of extracellular matrices (ECM) and methods of treatment of diseases, conditions and symptoms related to vascular permeability such as pulmonary edema and acute respiratory distress syndrome (ARDS). The modulation can be increasing or decreasing vascular permeability. Vascular leakage can be normalized by increasing or decreasing ECM stiffness depending on the baseline mechanical properties of the tissue or organ. Vascular permeability is altered by changing the mechanical properties of ECM by administering a lysyl oxidase modulating (LOX) agent.

Claims (5)

1. A method of decreasing vascular permeability in a tissue or organ of a subject in need of treatment for a pulmonary disease selected from acute respiratory distress syndrome (ARDS), pulmonary edema, endotoxin-induced lung injury, pulmonary embolism, pleural effusion, or sepsis, the method comprising:

administering an agent that decreases the stiffness of the extracellular matrix (ECM) to a subject in need thereof wherein the agent is a lysyl oxidase (LOX) inhibitor selected from the group consisting of:

a lysyl oxidase (LOX) siRNA, a peptide having the sequence EDTSCDYGYHRRFA (SEQ ID NO: 1), or a purified antibody that binds specifically to the sequence EDTSCDYGYHRRFA (SEQ ID NO: 1).

2. The method of claim 1 , further comprising measuring the ECM in the subject before treatment.

3. The method of claim 1 , wherein the agent is administered via aerosol delivery into the subject's lung.

Assignments (1)
CONFIRMATORY LICENSE Recorded May 15, 2017
From: BOSTON CHILDREN'S HOSPITAL
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 042459/0287 →
Continuity (2)
Provisional Application 61788714 · Mar 15, 2013
Related Publication 20160008421A1 · Jan 14, 2016